MRSA Antibody Therapeutic Simultaneously Treats and Vaccinates Against Reinfection
University of Chicago, IL, United States
A monoclonal antibody that demonstrates effectiveness as both a treatment and vaccine for Staphylococcus aureus infections. The therapeutic antibody vaccine is effective in treating methicillin-resistant S. aureus (MRSA) infection by enabling bacterial killing and generating a protective immune response that prevents recurrence.
Primary Application Area: Biotech & Biological Sciences
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: Protects against several S. aureus strains, offering a single treatment solution for potentially all S. aureus infections. Avoids toxicities associated with the use of antibiotics currently used. Targets a highly conserved protein, minimizing re-emergence.
Organization Type: Academic/Gov Lab
Showcase Booth #: 637
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: The MRSA antibody therapeutic discovery, optimization, and lead identification has been supported by NIH awards in excess of $1M and distributed over four years.
Primary Sources of Funding: Federal Grant
Looking for: Both Funding and Development Partners